Open AccessSecukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
Author(s) -
Lin Cai,
Jianzhong Zhang,
Xu Yao,
Jun Gu,
Quanzhong Liu,
Min Zheng,
Shifa Zhang,
Jianhua Xu,
ChengXin Li,
Hao Cheng,
Qing Guo,
Weili Pan,
Shenqiu Li,
Ruoyu Li,
Zhanfang Guo,
Zhiqi Song,
Shanshan Li,
Xiuqin Dong,
Linda Wang,
Rong Fu,
P. Regnault,
Pascal Charef,
Rafał Mazur,
Manmath Patekar
Publication year - 2020
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000001163
Subject(s) - secukinumab , medicine , placebo , psoriasis , adverse effect , psoriasis area and severity index , clinical endpoint , plaque psoriasis , randomized controlled trial , population , clinical trial , dermatology , psoriatic arthritis , pathology , alternative medicine , environmental health
Psoriasis is a chronic inflammatory skin disease, affecting about 0.6% of the Chinese population. Many patients are not well controlled by conventional treatments, thus there is need for new treatment regimens. In this study, we assessed the efficacy and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis.